Evidence map›Paper›PMID 42903730›Full record

ArticleClinical & translational immunology2026

Spatial and maturational characterisation of tertiary lymphoid structures predicts immunotherapy response in extensive-stage small cell lung cancer.

Haoyu Wang, Xiaoling Shang, Yuanzhu Jiang, Chenglong Zhao, Zhenxiang Li, Chufeng Zhang, Qinhao Xu, Shanshan Du, Jiamao Lin, Haiyong Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical & translational immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Haoyu WangDepartment of Internal Medicine-Oncology, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan China.
Xiaoling ShangDepartment of Internal Medicine-Oncology, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan China.
Yuanzhu JiangDepartment of Radiation Oncology Shandong Provincial Hospital Affiliated to Shandong First Medical University Jinan China.
Chenglong ZhaoDepartment of Pathology The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital Jinan Shandong China.
Zhenxiang LiDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan China.ORCID https://orcid.org/0000-0002-9648-8869
Chufeng ZhangDepartment of Internal Medicine-Oncology, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan China.
Qinhao XuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan China.
Shanshan DuDepartment of Internal Medicine-Oncology, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan China.
Jiamao LinDepartment of Internal Medicine-Oncology, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan China.
Haiyong WangDepartment of Internal Medicine-Oncology, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan China.ORCID https://orcid.org/0009-0006-4732-9972

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Extensive-stage small cell lung cancer (ES-SCLC) remains an aggressive malignancy with limited durable responses to immune checkpoint inhibitors (ICIs) and no established predictive biomarkers. This study aimed to evaluate the prognostic and predictive value of tertiary lymphoid structures (TLSs) in patients with ES-SCLC receiving ICI-based therapy. Methods: In this multicenter retrospective study of 180 treatment-naïve ES-SCLC patients subsequently receiving ICI-based therapy, TLSs were systematically evaluated using H&E staining, multiplex immunofluorescence, and spatial analysis to determine their prognostic and predictive value. Results: TLSs were identified in 22.2% of cases and independently associated with improved overall survival (OS) in both univariate (HR = 0.365, 95% CI: 0.217-0.613, Conclusion: TLS maturation and spatial architecture may serve as candidate tissue biomarkers associated with clinical outcomes in ICI-treated ES-SCLC, warranting prospective validation alongside SCLC molecular subtyping.

Indexed as

extensive‐stage small cell lung cancerimmune checkpoint inhibitorsspatial architecturetertiary lymphoid structuresTLS maturation

Identifiers

PMID42903730
PMCPMC13682280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.